A pharmaceutical company expanded its prior recall of anti-anxiety drug clonazepam tablets due to a potential “mislabeling” about the product’s strength on its carton that could be “life-threatening,” according to an announcement published by the U.S. Food and Drug Administration (FDA).
In the notice updated Nov. 19, Endo Inc. said that the impacted products, already under recall, are Clonazepam Orally Disintegrating Tablets, USP.
An ongoing investigation initiated by the firm shows there is a chance more impacted product lots “contain a limited number of cartons printed with the incorrect strength” and incorrect National Drug Code because of “an error by a third-party packager,” it said….